ArticleScientific reports2025
Immune profiling of canine B cell lymphoma reveals cross-species conservation of prognostic markers.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Only 60% of patients with diffuse large B cell lymphoma are cured following standard of care therapies. While immune contexture is associated with outcomes in patients treated with chemotherapy, immune mechanisms driving differential therapeutic responses remain unclear. Here, we undertook a comparative analysis of dogs with spontaneous B cell lymphoma (BCL), which exhibit similar dichotomies in therapeutic outcome, to identify conserved and species-specific transcriptional and circulating biomarkers associated with remission duration. In addition, we compared treatment naive and relapsed samples to determine how treatment impacts immune contexture at the time of treatment failure. Among eighteen client-owned dogs with aggressive BCL undergoing multi-agent chemotherapy, comparative immune profiling revealed increased T cell transcripts associated with prolonged remissions and, as in humans, IL2RB expression was associated with favorable outcomes. Increased angiogenic markers were associated with shorter remissions. In treatment naive samples, macrophage associated cytokines were increased, whereas multiple T cell-associated transcripts were enriched in relapsed nodes. Collectively, our findings reveal that changes in immune composition are associated with varying chemotherapeutic outcomes in canine BCL and highlight the potential for comparative oncology approaches to identify factors associated with disease progression, providing insight for development and testing of novel therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.